-
Mashup Score: 0‘High-tech, high-touch’ patient care key to improving chronic conditions like Crohn’s - 11 month(s) ago
The prospect of managing a lifelong disease can be daunting, and many patients with chronic conditions struggle with consistent health monitoring, treatment adherence and implementing the changes needed to manage their disease. From the provider perspective, physicians may have limited visibility into how patients are coping with or adhering to treatment regimens — until they present with
Source: www.healio.comCategories: Gastroenterology, Latest HeadlinesTweet
-
Mashup Score: 2More than 60% of Crohn’s patients sustained remission with subcutaneous biosimilar CT-P13 - 12 month(s) ago
CHICAGO — Subcutaneous maintenance therapy with an infliximab biosimilar after IV induction resulted in sustained clinical remission and greater endoscopic response vs. placebo in patients with moderate to severe Crohn’s disease. “In the past several years, there have been a number of formulations of infliximab that have met criteria for what is known as biosimilarity,”
Source: www.healio.comCategories: Gastroenterology, Latest HeadlinesTweet-
Subcutaneous maintenance therapy with an #infliximab biosimilar after IV induction resulted in sustained clinical remission and greater endoscopic response vs. placebo in patients with moderate to severe #Crohnsdisease. #DDW23 @NMH_SHanauerMD https://t.co/SYpUQSBi4D
-
-
Mashup Score: 0TiO2 nanoparticles abrogate the protective effect of the Crohn’s disease-associated variation within the PTPN22 gene locus - 12 month(s) ago
Objective Inflammatory bowel disease (IBD) is a multifactorial condition driven by genetic and environmental risk factors. A genetic variation in the protein tyrosine phosphatase non-receptor type 22 (PTPN22) gene has been associated with autoimmune disorders while protecting from the IBD subtype Crohn’s disease. Mice expressing the murine orthologous PTPN22-R619W variant are protected from…
Source: GutCategories: Gastroenterology, Latest HeadlinesTweet-
#GUTImage from the paper by Schwarzfischer et al entitled "TiO2 nanoparticles abrogate the protective effect of the Crohn’s disease-associated variation within the PTPN22 gene locus" via https://t.co/O3v3ATryCY #CrohnsDisease #IBD https://t.co/kGDcbDRlUD
-
-
Mashup Score: 2Wolters Kluwer Health - 12 month(s) ago
JavaScript Error JavaScript has been disabled on your browser. You must enable it to continue. Here’s how to enable JavaScript in the following browsers: Internet Explorer From the Tools menu, select Options Click the Content tab Select Enable JavaScript Firefox From the Tools…
Source: lww.comCategories: Latest Headlines, PediatricsTweet-
Choi et al evaluate methotrexate as first line therapy in pediatric #CrohnsDisease: 🟰 Clinical remission rate in thiopurine-naive comparable to other immunomodulators 🚫 No significant adverse effects 📆 Sustained improvements for at least a year https://t.co/yNKSjW2Jag https://t.co/7m0YHWZBLy
-
-
Mashup Score: 0TiO2 nanoparticles abrogate the protective effect of the Crohn’s disease-associated variation within the PTPN22 gene locus - 12 month(s) ago
Objective Inflammatory bowel disease (IBD) is a multifactorial condition driven by genetic and environmental risk factors. A genetic variation in the protein tyrosine phosphatase non-receptor type 22 (PTPN22) gene has been associated with autoimmune disorders while protecting from the IBD subtype Crohn’s disease. Mice expressing the murine orthologous PTPN22-R619W variant are protected from…
Source: GutCategories: Gastroenterology, Latest HeadlinesTweet-
#GUTImage from the paper by Schwarzfischer et al entitled "TiO2 nanoparticles abrogate the protective effect of the Crohn’s disease-associated variation within the PTPN22 gene locus" via https://t.co/O3v3ATryCY #CrohnsDisease #IBD https://t.co/N6xyCeEj6J
-
-
Mashup Score: 0TiO2 nanoparticles abrogate the protective effect of the Crohn’s disease-associated variation within the PTPN22 gene locus - 12 month(s) ago
Objective Inflammatory bowel disease (IBD) is a multifactorial condition driven by genetic and environmental risk factors. A genetic variation in the protein tyrosine phosphatase non-receptor type 22 (PTPN22) gene has been associated with autoimmune disorders while protecting from the IBD subtype Crohn’s disease. Mice expressing the murine orthologous PTPN22-R619W variant are protected from…
Source: GutCategories: Gastroenterology, Latest HeadlinesTweet-
#GUTImage from the paper by Schwarzfischer et al entitled "TiO2 nanoparticles abrogate the protective effect of the Crohn’s disease-associated variation within the PTPN22 gene locus" via https://t.co/O3v3ATryCY #CrohnsDisease #IBD https://t.co/yoduOqkZx1
-
-
Mashup Score: 1
The FDA has approved AbbVie’s Rinvoq as a once-day pill intended for the treatment of adult patients with moderate to severe Crohn’s disease who are intolerant, or have had an inadequate response, to one or more TNF inhibitors. Upadacitinib (Rinvoq, AbbVie)v is now indicated for both Crohn’s disease and ulcerative colitis. Additionally, this decision marks the drug’s
Source: www.healio.comCategories: Gastroenterology, Latest HeadlinesTweet-
#ICYMI: @US_FDA approves #Rinvoq as first oral therapy for moderate to severe #Crohnsdisease @abbvie #GITwitter https://t.co/Gbj9xV4x1R
-
-
Mashup Score: 0
The FDA has approved AbbVie’s Rinvoq as a once-day pill intended for the treatment of adult patients with moderate to severe Crohn’s disease who are intolerant, or have had an inadequate response, to one or more TNF inhibitors. Upadacitinib (Rinvoq, AbbVie)v is now indicated for both Crohn’s disease and ulcerative colitis. Additionally, this decision marks the drug’s
Source: www.healio.comCategories: General Medicine News, Latest HeadlinesTweet-
BREAKING NEWS! The FDA has approved Rinvoq as first oral therapy for refractory patients with moderate to severe Crohn’s disease. #FDAapproval #crohnsdisease https://t.co/cRuYmSzHBs
-
-
Mashup Score: 0
The FDA has approved AbbVie’s Rinvoq as a once-day pill intended for the treatment of adult patients with moderate to severe Crohn’s disease who are intolerant, or have had an inadequate response, to one or more TNF inhibitors. Upadacitinib (Rinvoq, AbbVie)v is now indicated for both Crohn’s disease and ulcerative colitis. Additionally, this decision marks the drug’s
Source: www.healio.comCategories: Gastroenterology, Latest HeadlinesTweet-
The @US_FDA has approved @abbvie’s #Rinvoq as a once-day pill intended for the treatment of adult patients with moderate to severe #Crohnsdisease who are intolerant, or have had an inadequate response, to one or more TNF inhibitors. #GITwitter https://t.co/Gbj9xV4x1R
-
-
Mashup Score: 0Immunoprophylaxis ‘does not seem superior’ to prevent postoperative Crohn’s recurrence - 1 year(s) ago
CHICAGO — Immediate immunoprophylaxis after curative ileo-colonic resection did not reduce the rate of early recurrence among patients with Crohn’s disease who only had one risk factor for postoperative recurrence. “As we all know, approximately half of our patients with Crohn’s disease will need at least one intestinal resection during their lifetime,” Gabriele
Source: www.healio.comCategories: Gastroenterology, Latest HeadlinesTweet-
Immediate #immunoprophylaxis after curative ileo-colonic resection did not reduce the rate of early recurrence among patients with #Crohnsdisease who only had one risk factor for postoperative recurrence. #DDW23 @DDWMeeting https://t.co/lSy5Z9MHrE
-
In an expert editorial, Antonio Perez, MD, MBA, FACC, FHFSA, of @ElevanceHealth discussed ‘high-tech, high-touch’ #patientcare for #CrohnsDisease. #GITwitter #MedTwitter https://t.co/Q5CpK2k6Y9